Comparing laser treatment and clobetasol for lichen sclerosus
CO2 Non-ablative Laser Versus Topical Clobetasol for Lichen Sclerosus: a Prospective, Open-label, Randomized Trial
This study is testing whether a laser treatment works better than a topical cream for women with lichen sclerosus to see which one helps relieve their symptoms more effectively.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 198 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Ruhr University of Bochum Academic / other |
| Locations | 1 site (Herne, NRW) |
| Trial ID | NCT05010421 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to compare the effectiveness of non-ablative CO2 laser treatment versus clobetasol 0.05% emollient top cream in women diagnosed with lichen sclerosus, a chronic autoimmune condition affecting the genital skin. The study will enroll women aged 18 and older who have been diagnosed with lichen sclerosus and are willing to comply with the study requirements. Participants will be monitored for improvements in symptoms such as itching, burning, and pain, as well as long-term outcomes related to the condition. The trial seeks to provide high-quality evidence on the efficacy of these two treatment modalities.
Who should consider this trial
Good fit: Ideal candidates for this study are women aged 18 and older with a confirmed diagnosis of lichen sclerosus affecting the vulva, perineum, or perianal region.
Not a fit: Patients with a history of vulvar cancer, concurrent immunosuppressive treatment, or other significant skin conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide clearer guidance on the most effective treatment for lichen sclerosus, potentially improving patient outcomes and quality of life.
How similar studies have performed: While both treatments are commonly used, direct comparative studies assessing their efficacy are rare, making this approach relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women, age ≥ 18 years * Established diagnosis of LS (vulva and/or perineum and/or perianal region) * Willingness to comply with study requirements * No significant language barrier Exclusion Criteria: * Concurrent immunosuppressive treatment * A history of vulvar cancer and/or vulvar dysplasia * A history of vulvar surgery * A contraindication against clobetasol treatment * A known sun light allergy * A known skin condition interfering with local ablative treatment such as neurodermatitis or bullous pemphigoid
Where this trial is running
Herne, NRW
- Marien Hospital Herne — Herne, Nrw, Germany (Recruiting)
Study contacts
- Principal investigator: Clemens B Tempfer, MD — Ruhr-Universität Bochum / Marien Hospital Herne
- Study coordinator: Clemens B Tempfer, MD
- Email: clemens.tempfer@rub.de
- Phone: +492323499
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.